Hypopituitarism in five PROP1 mutation siblings: long-lasting natural course and the effects of growth hormone replacement introduction in middle adulthood

Doknic, Mirjana; Gašić, Vladimir; Stojanović, Marko; Pavlović, Sonja; Marinkovic, Snezana; Miljić, Dragana; Pekić, Sandra; Manojlović-Gačić, Emilija; Damjanovic, Dusan; Soldatović, Ivan; Petakov, Мilan

doi:10.1007/s11102-020-01049-9

Cited by 3 publications

(1 citation statement)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The clinical implications associated with the anatomical location of glioblastoma were analyzed in different articles, with a total of 107 articles in which a relationship was not made between the region of glioblastoma and a clinical implication [10,11,13,[18][19][20][21][22][70][71][72][73][74][75][77][78][79][80][81][82][83][84][85][87][88][89][90][91][92][93][94][95][96][97][98][99][100]104,105,[107][108][109][110][111][112][113][114][115][116]…”

Section: Discussionmentioning

confidence: 99%

Association between the Anatomical Location of Glioblastoma and Its Evaluation with Clinical Considerations: A Systematic Review and Meta-Analysis

Valenzuela-Fuenzalida,

Moyano-Valarezo,

Silva-Bravo

et al. 2024

JCM

View full text Add to dashboard Cite

Background: Glioblastoma is a primary malignant brain tumor; it is aggressive with a high degree of malignancy and unfavorable prognosis and is the most common type of malignant brain tumor. Glioblastomas can be located in the brain, cerebellum, brainstem, and spinal cord, originating from glial cells, particularly astrocytes. Methods: The databases MEDLINE, Scopus, Web of Science, Google Scholar, and CINAHL were researched up to January 2024. Two authors independently performed the search, study selection, and data extraction. Methodological quality was evaluated with an assurance tool for anatomical studies (AQUA). The statistical mean, standard deviation, and difference of means calculated with the Student’s t-test for presence between hemispheres and presence in the frontal and temporal lobes were analyzed. Results: A total of 123 studies met the established selection criteria, with a total of 6224 patients. In relation to the mean, GBM between hemispheres had a mean of 33.36 (SD 58.00) in the right hemisphere and a mean of 34.70 (SD 65.07) in the left hemisphere, due to the difference in averages between hemispheres. There were no statistically significant differences, p = 0.35. For the comparison between the presence of GBM in the frontal lobe and the temporal lobe, there was a mean in the frontal lobe of 23.23 (SD 40.03), while in the temporal lobe, the mean was 22.05 (SD 43.50), and for the difference in means between the frontal lobe and the temporal lobe, there was no statistically significant difference for the presence of GBM, p = 0.178. Conclusions: We believe that before a treatment, it will always be correct to know where the GBM is located and how it behaves clinically, in order to generate correct conservative or surgical treatment guidelines for each patient. We believe that more detailed studies are also needed to show why GBM is associated more with some regions than others, despite the brain structure being homologous to other regions in which GMB occurs less frequently, which is why knowing its predominant presence in brain regions is very important.

show abstract

Section: Discussionmentioning

confidence: 99%

Association between the Anatomical Location of Glioblastoma and Its Evaluation with Clinical Considerations: A Systematic Review and Meta-Analysis

Valenzuela-Fuenzalida,

Moyano-Valarezo,

Silva-Bravo

et al. 2024

JCM

View full text Add to dashboard Cite

show abstract

Position statement on the diagnosis and management of congenital pituitary deficiency in adults: The French National Diagnosis and Treatment Protocol (NDTP)

Castets,

Albarel,

Bachelot

et al. 2024

Annales d'Endocrinologie

View full text Add to dashboard Cite

Growth hormone deficiency in adults: Diagnosis and treatment

Doknić

2024

Galenika Med J

Self Cite

View full text Add to dashboard Cite

Growth hormone deficiency (GHD) in adults is a rare clinical syndrome with an incidence of 1.4-4.2 per 100,000 persons per year and a prevalence of 350/million. It is characterized by unfavorable body composition, reduced muscle, and bone mass, lower capacity to endure physical effort, abnormal lipid profile, increased cardiovascular risk and poor quality of life. Despite these clinical manifestations, GHD is often unrecognized, so its diagnosis is often missed or delayed. The reason is the non-specific and subtle clinical characteristics, which require the testing of growth hormone (GH) secretion with stimulation tests. Two tests are in use, the insulin tolerance test and the glucagon test, which require the experience of the team performing them. Recently, an oral secretagogue of growth hormone - macimorelin has been used, which is simple test to perform and is safe for the patient. Insufficient secretion of GH in adults can be manifested as isolated or in combination with deficits of other pituitary hormones. However, GH is the most frequently detected hormonal deficit in adults as part of hypopituitarism. Causes of GHD can be congenital or acquired. Congenital reasons are the result of disorders of the embryogenic development of the pituitary gland and hypothalamus, and acquired are the most common complications of tumors of the sellar region and head trauma. Patients with GHD have an increased mortality rate compared to the general population. The causes of the shortened life span of these patients depend on the etiology of hypopituitarism, the applied therapy of tumors of the hypothalamus/pituitary region (surgery, radiotherapy), and the replacement of other missing pituitary hormones. During the last two decades, growth hormone therapy in adults has entered routine clinical practice. The beneficial effects of this substitution are reflected in the body composition, skeletal system, metabolic status, and improvement of the quality of life. GH replacement in adults returns the mortality rate to that expected for age in the general population. Due to the known proliferative, angiogenic, and anti-apoptotic properties of GH, there is still some caution regarding the recurrence of hypopituitarism-causing tumors or the appearance of new tumors during GH replacement. However, large and long-term follow-up studies of adults on GH therapy have shown a high safety profile of this treatment. Daily injections of GH were until recently the only way of its application, and now longacting weekly forms have been marketed, which will significantly improve adherence to this therapy.

show abstract

Hypopituitarism in five PROP1 mutation siblings: long-lasting natural course and the effects of growth hormone replacement introduction in middle adulthood

Cited by 3 publications

References 43 publications

Association between the Anatomical Location of Glioblastoma and Its Evaluation with Clinical Considerations: A Systematic Review and Meta-Analysis

Association between the Anatomical Location of Glioblastoma and Its Evaluation with Clinical Considerations: A Systematic Review and Meta-Analysis

Position statement on the diagnosis and management of congenital pituitary deficiency in adults: The French National Diagnosis and Treatment Protocol (NDTP)

Growth hormone deficiency in adults: Diagnosis and treatment

Contact Info

Product

Resources

About